Pharmacogenomic identification of targets for adjuvant therapy with the topoisomerase poison camptothecin
Pharmacogenomic identification of targets for adjuvant therapy with the topoisomerase poison camptothecin
复制标题
DOI：
10.1158/0008-5472.can-03-2029
复制
发表时间：
2004-03-15
期刊：
影响因子：
11.2
通讯作者：
Christman, MF
中科院分区：
文献类型：
--
作者：
Carson, JP;Zhang, NY;Christman, MF
肿瘤细胞对由拓扑异构酶毒物如喜树碱（CPT）引起的不寻常形式的DNA损伤的反应知之甚少，并且缺乏关于哪些药物可以有效地与CPT组合的知识。为了更好地了解肿瘤细胞对CPT的反应并确定辅助治疗的潜在靶点，我们使用Affytron U133 A GeneChips检查了CPT治疗后HeLa细胞中mRNA丰度的总体变化，其中包括所有注释的人类基因（22，283个探针集）。使用Bayesian/ Cyber t检验和用于多个假设检验的修改的Benjamini和Hochberg校正对数据进行统计学分析，鉴定了CPT处理后8小时诱导的188个探针组和抑制的495个探针组，假发现率为
The response of tumor cells to the unusual form of DNA damage caused by topoisomerase poisons such as camptothecin (CPT) is poorly understood, and knowledge regarding which drugs can be effectively combined with CPT is lacking. To better understand the response of tumor cells to CPT and to identify potential targets for adjuvant therapy, we examined global changes in mRNA abundance in HeLa cells after CPT treatment using Affymetrix U133A GeneChips, which include all annotated human genes (22,283 probe sets). Statistical analysis of the data using a Bayesian/ Cyber t test and a modified Benjamini and Hochberg correction for multiple hypotheses testing identified 188 probe sets that are induced and 495 that are repressed 8 h after CPT treatment at a False Discovery Rate of